{"transactions":[{"id":764749,"issuer":{"id":4363,"kind":"organization","name":"Bausch Health Companies Inc."},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":true}}],"security":"Common Shares, No Par Value","published_at":"2026-05-26T23:02:25.000Z","date":"2026-05-22","kind":"grant","planned":false,"acquired":true,"shares":45871,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the award of restricted share units (\"RSUs\") granted to non-employee directors of the Issuer on the third business day following their election at the Issuer's Annual Meeting of Shareholders. The RSUs have a grant date value of $250,000, vest on the date immediately preceding the Issuer's next Annual Meeting of Shareholders, and are settled in common shares, no par value, of the Issuer."}],"balance_after":45871,"source":{"system":"sec-edgar","filing":"0000885590-26-000082","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/885590/000088559026000082/form4.xml","form_type":"4"}},{"id":800257,"issuer":{"id":51196,"kind":"organization","name":"AMICUS THERAPEUTICS, INC.","symbol":"FOLD"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2026-04-27T20:41:52.000Z","date":"2026-04-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":74872,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"In connection with consummation of the Merger, each reported stock option (\"Option\") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with consummation of the Merger, each reported stock option (\"Option\") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each Option vested in full in connection with consummation of the Merger."}],"balance_after":0,"derivative":{"exercise_price":5.96,"expiration_date":"2035-06-05","underlying":"Common Stock","underlying_shares":74872},"source":{"system":"sec-edgar","filing":"0001193125-26-182275","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1178879/000119312526182275/ownership.xml","form_type":"4"}},{"id":800256,"issuer":{"id":51196,"kind":"organization","name":"AMICUS THERAPEUTICS, INC.","symbol":"FOLD"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2026-04-27T20:41:52.000Z","date":"2026-04-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":42467,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"In connection with consummation of the Merger, each reported stock option (\"Option\") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with consummation of the Merger, each reported stock option (\"Option\") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each Option was fully vested."}],"balance_after":0,"derivative":{"exercise_price":10.27,"expiration_date":"2034-06-06","underlying":"Common Stock","underlying_shares":42467},"source":{"system":"sec-edgar","filing":"0001193125-26-182275","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1178879/000119312526182275/ownership.xml","form_type":"4"}},{"id":800255,"issuer":{"id":51196,"kind":"organization","name":"AMICUS THERAPEUTICS, INC.","symbol":"FOLD"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2026-04-27T20:41:52.000Z","date":"2026-04-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":30474,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"In connection with consummation of the Merger, each reported stock option (\"Option\") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with consummation of the Merger, each reported stock option (\"Option\") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each Option was fully vested."}],"balance_after":0,"derivative":{"exercise_price":12.62,"expiration_date":"2033-06-08","underlying":"Common Stock","underlying_shares":30474},"source":{"system":"sec-edgar","filing":"0001193125-26-182275","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1178879/000119312526182275/ownership.xml","form_type":"4"}},{"id":800254,"issuer":{"id":51196,"kind":"organization","name":"AMICUS THERAPEUTICS, INC.","symbol":"FOLD"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2026-04-27T20:41:52.000Z","date":"2026-04-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":45423,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"In connection with consummation of the Merger, each reported stock option (\"Option\") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with consummation of the Merger, each reported stock option (\"Option\") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each Option was fully vested."}],"balance_after":0,"derivative":{"exercise_price":8.55,"expiration_date":"2032-06-09","underlying":"Common Stock","underlying_shares":45423},"source":{"system":"sec-edgar","filing":"0001193125-26-182275","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178879/000119312526182275/ownership.xml","form_type":"4"}},{"id":800253,"issuer":{"id":51196,"kind":"organization","name":"AMICUS THERAPEUTICS, INC.","symbol":"FOLD"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2026-04-27T20:41:52.000Z","date":"2026-04-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":40625,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"In connection with consummation of the Merger, each reported stock option (\"Option\") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with consummation of the Merger, each reported stock option (\"Option\") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each Option was fully vested."}],"balance_after":0,"derivative":{"exercise_price":10.71,"expiration_date":"2031-06-10","underlying":"Common Stock","underlying_shares":40625},"source":{"system":"sec-edgar","filing":"0001193125-26-182275","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178879/000119312526182275/ownership.xml","form_type":"4"}},{"id":800252,"issuer":{"id":51196,"kind":"organization","name":"AMICUS THERAPEUTICS, INC.","symbol":"FOLD"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-27T20:41:52.000Z","date":"2026-04-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":76275,"price":14.5,"value":1105987.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported securities were disposed of in connection with consummation of the acquisition of the Issuer by BioMarin Pharmaceutical Inc. (the \"Merger\"), which included 55,861 shares of Common Stock and 20,414 restricted stock units (which vested in full in connection with consummation of the Merger)."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-26-182275","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178879/000119312526182275/ownership.xml","form_type":"4"}},{"id":1120051,"issuer":{"id":51196,"kind":"organization","name":"AMICUS THERAPEUTICS, INC.","symbol":"FOLD"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2025-06-06T20:53:23.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":74872,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One hundred percent of the shares subject to this option will vest and become exercisable on the one year anniversary of the date of grant."}],"balance_after":74872,"derivative":{"exercise_price":5.96,"expiration_date":"2035-06-05","underlying":"Common Stock","underlying_shares":74872},"source":{"system":"sec-edgar","filing":"0000950170-25-083215","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178879/000095017025083215/ownership.xml","form_type":"4"}},{"id":1120050,"issuer":{"id":51196,"kind":"organization","name":"AMICUS THERAPEUTICS, INC.","symbol":"FOLD"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-06T20:53:23.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":20414,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Granted in the form of Restricted Stock Units (\"RSUs\"), these RSUs will vest in full on the one year anniversary of the grant date and shall be payable in common stock. One (1) RSU is the equivalent of one (1) share of Amicus common stock."}],"balance_after":76275,"source":{"system":"sec-edgar","filing":"0000950170-25-083215","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178879/000095017025083215/ownership.xml","form_type":"4"}},{"id":1268338,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Unit","published_at":"2025-02-14T23:42:06.000Z","date":"2025-02-13","kind":"exercise","planned":true,"acquired":false,"shares":1372,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F8","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"This RSU was granted to the Reporting Person on December 17, 2024.  In accordance with the terms of the RSU, the award vested as to 1,372 shares on February 13, 2025, and will vest as to 1,372 shares on February 13, 2026, 1,372 shares on February 13, 2027, and 1,371 shares on February 13, 2028, subject to the terms and conditions of the award."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F12","text":"This RSU was granted to the Reporting Person on December 17, 2024.  In accordance with the terms of the RSU, the award vested as to 1,372 shares on February 13, 2025, and will vest as to 1,372 shares on February 13, 2026, 1,372 shares on February 13, 2027, and 1,371 shares on February 13, 2028, subject to the terms and conditions of the award."}],"balance_after":4115,"derivative":{"underlying":"Common Stock","underlying_shares":1372},"source":{"system":"sec-edgar","filing":"0000914475-25-000069","document":"wk-form4_1739576520.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000069/wk-form4_1739576520.xml","form_type":"4"}},{"id":1268337,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Unit","published_at":"2025-02-14T23:42:06.000Z","date":"2025-02-13","kind":"exercise","planned":true,"acquired":false,"shares":1120,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F8","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"This RSU was granted to the Reporting Person on February 13, 2024.  In accordance with the terms of the RSU, the award vested as to 1,120 shares on February 13, 2025, and will vest as to 1,121 shares on February 13, 2026, 1,121 shares on February 13, 2027, and 1,121 shares on February 13, 2028, subject to the terms and conditions of the award."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F11","text":"This RSU was granted to the Reporting Person on February 13, 2024.  In accordance with the terms of the RSU, the award vested as to 1,120 shares on February 13, 2025, and will vest as to 1,121 shares on February 13, 2026, 1,121 shares on February 13, 2027, and 1,121 shares on February 13, 2028, subject to the terms and conditions of the award."}],"balance_after":3363,"derivative":{"underlying":"Common Stock","underlying_shares":1120},"source":{"system":"sec-edgar","filing":"0000914475-25-000069","document":"wk-form4_1739576520.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000069/wk-form4_1739576520.xml","form_type":"4"}},{"id":1268336,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Unit","published_at":"2025-02-14T23:42:06.000Z","date":"2025-02-13","kind":"exercise","planned":true,"acquired":false,"shares":2113,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F8","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"This RSU was granted to the Reporting Person on February 13, 2023.  In accordance with the terms of the RSU, the award vested as to 2,113 shares on February 13, 2024, vested as to 2,113 shares on February 13, 2025, and will vest as to 2,113 shares on February 13, 2026, and 2,114 shares on February 13, 2027, subject to the terms and conditions of the award."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F10","text":"This RSU was granted to the Reporting Person on February 13, 2023.  In accordance with the terms of the RSU, the award vested as to 2,113 shares on February 13, 2024, vested as to 2,113 shares on February 13, 2025, and will vest as to 2,113 shares on February 13, 2026, and 2,114 shares on February 13, 2027, subject to the terms and conditions of the award."}],"balance_after":4227,"derivative":{"underlying":"Common Stock","underlying_shares":2113},"source":{"system":"sec-edgar","filing":"0000914475-25-000069","document":"wk-form4_1739576520.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000069/wk-form4_1739576520.xml","form_type":"4"}},{"id":1268335,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Unit","published_at":"2025-02-14T23:42:06.000Z","date":"2025-02-12","kind":"grant","planned":true,"acquired":true,"shares":8108,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F8","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 12, 2026, February 12, 2027, February 12, 2028, and February 12, 2029."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 12, 2026, February 12, 2027, February 12, 2028, and February 12, 2029."}],"balance_after":8108,"derivative":{"underlying":"Common Stock","underlying_shares":8108},"source":{"system":"sec-edgar","filing":"0000914475-25-000069","document":"wk-form4_1739576520.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000069/wk-form4_1739576520.xml","form_type":"4"}},{"id":1268334,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option","published_at":"2025-02-14T23:42:06.000Z","date":"2025-02-12","kind":"grant","planned":true,"acquired":true,"shares":43261,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 12, 2025 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter."}],"balance_after":43261,"derivative":{"exercise_price":117.18,"expiration_date":"2035-02-12","underlying":"Common Stock","underlying_shares":43261},"source":{"system":"sec-edgar","filing":"0000914475-25-000069","document":"wk-form4_1739576520.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000069/wk-form4_1739576520.xml","form_type":"4"}},{"id":1268333,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-02-14T23:42:06.000Z","date":"2025-02-14","kind":"sale","planned":true,"acquired":false,"shares":500,"price":115.0425,"value":57521.25,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $114.76 to $115.15. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"34,455 of the outstanding shares are held by The Stephen Taylor and Eiry W. Roberts Joint Trust Agreement, of which Dr. Roberts has voting and investment power."}],"balance_after":35640,"source":{"system":"sec-edgar","filing":"0000914475-25-000069","document":"wk-form4_1739576520.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000069/wk-form4_1739576520.xml","form_type":"4"}},{"id":1268332,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-02-14T23:42:06.000Z","date":"2025-02-13","kind":"exercise","planned":true,"acquired":true,"shares":1372,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":36140,"source":{"system":"sec-edgar","filing":"0000914475-25-000069","document":"wk-form4_1739576520.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000069/wk-form4_1739576520.xml","form_type":"4"}},{"id":1268331,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-02-14T23:42:06.000Z","date":"2025-02-13","kind":"sale","planned":true,"acquired":false,"shares":604,"price":116.7391,"value":70510.4164,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2024. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.98 to $118.28. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":34768,"source":{"system":"sec-edgar","filing":"0000914475-25-000069","document":"wk-form4_1739576520.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000069/wk-form4_1739576520.xml","form_type":"4"}},{"id":1268330,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-02-14T23:42:06.000Z","date":"2025-02-13","kind":"exercise","planned":true,"acquired":true,"shares":1120,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":35372,"source":{"system":"sec-edgar","filing":"0000914475-25-000069","document":"wk-form4_1739576520.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000069/wk-form4_1739576520.xml","form_type":"4"}},{"id":1268329,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-02-14T23:42:06.000Z","date":"2025-02-13","kind":"sale","planned":true,"acquired":false,"shares":1114,"price":116.9049,"value":130232.0586,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $116.24 to $117.53. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":34252,"source":{"system":"sec-edgar","filing":"0000914475-25-000069","document":"wk-form4_1739576520.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000069/wk-form4_1739576520.xml","form_type":"4"}},{"id":1268328,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-02-14T23:42:06.000Z","date":"2025-02-13","kind":"exercise","planned":true,"acquired":true,"shares":2113,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":35366,"source":{"system":"sec-edgar","filing":"0000914475-25-000069","document":"wk-form4_1739576520.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000069/wk-form4_1739576520.xml","form_type":"4"}},{"id":1272434,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Unit","published_at":"2025-02-12T23:52:24.000Z","date":"2025-02-08","kind":"exercise","planned":true,"acquired":false,"shares":1860,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This RSU was granted to the Reporting Person on February 8, 2021.  In accordance with the terms of the RSU, the award vested as to 1,859 shares on February 8, 2022, vested as to 1,860 shares on February 8, 2023, vested as to 1,860 shares on February 8, 2024, and vested as to 1,860 shares on February 8, 2025, subject to the terms and conditions of the award."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"This RSU was granted to the Reporting Person on February 8, 2021.  In accordance with the terms of the RSU, the award vested as to 1,859 shares on February 8, 2022, vested as to 1,860 shares on February 8, 2023, vested as to 1,860 shares on February 8, 2024, and vested as to 1,860 shares on February 8, 2025, subject to the terms and conditions of the award."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1860},"source":{"system":"sec-edgar","filing":"0000914475-25-000051","document":"wk-form4_1739404337.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000051/wk-form4_1739404337.xml","form_type":"4"}},{"id":1272433,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-02-12T23:52:24.000Z","date":"2025-02-10","kind":"sale","planned":true,"acquired":false,"shares":980,"price":118.217,"value":115852.66,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2021. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $116.07 to $123.53. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"32,068 of the outstanding shares are held by The Stephen Taylor and Eiry W. Roberts Joint Trust Agreement, of which Dr. Roberts has voting and investment power."}],"balance_after":33253,"source":{"system":"sec-edgar","filing":"0000914475-25-000051","document":"wk-form4_1739404337.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000051/wk-form4_1739404337.xml","form_type":"4"}},{"id":1272432,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-02-12T23:52:24.000Z","date":"2025-02-08","kind":"exercise","planned":true,"acquired":true,"shares":1860,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":34233,"source":{"system":"sec-edgar","filing":"0000914475-25-000051","document":"wk-form4_1739404337.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000051/wk-form4_1739404337.xml","form_type":"4"}},{"id":1285995,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Unit","published_at":"2025-02-04T22:54:59.000Z","date":"2025-01-31","kind":"exercise","planned":true,"acquired":false,"shares":2769,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 2,768 shares on January 31, 2023, vested as to 2,768 shares on January 31, 2024, vested as to 2,769 shares on January 31, 2025, and will vest as to 2,769 shares on January 31, 2026, subject to the terms and conditions of the award."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 2,768 shares on January 31, 2023, vested as to 2,768 shares on January 31, 2024, vested as to 2,769 shares on January 31, 2025, and will vest as to 2,769 shares on January 31, 2026, subject to the terms and conditions of the award."}],"balance_after":2769,"derivative":{"underlying":"Common Stock","underlying_shares":2769},"source":{"system":"sec-edgar","filing":"0000914475-25-000029","document":"wk-form4_1738709691.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000029/wk-form4_1738709691.xml","form_type":"4"}},{"id":1285994,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-02-04T22:54:59.000Z","date":"2025-01-31","kind":"sale","planned":true,"acquired":false,"shares":1457,"price":152.8045,"value":222636.1565,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 1, 2022. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $151.94 to $153.31. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"31,188 of the outstanding shares are held by The Stephen Taylor and Eiry W. Roberts Joint Trust Agreement, of which Dr. Roberts has voting and investment power"}],"balance_after":32373,"source":{"system":"sec-edgar","filing":"0000914475-25-000029","document":"wk-form4_1738709691.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000029/wk-form4_1738709691.xml","form_type":"4"}},{"id":1285993,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-02-04T22:54:59.000Z","date":"2025-01-31","kind":"exercise","planned":true,"acquired":true,"shares":2769,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":33830,"source":{"system":"sec-edgar","filing":"0000914475-25-000029","document":"wk-form4_1738709691.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000029/wk-form4_1738709691.xml","form_type":"4"}},{"id":1325814,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option","published_at":"2024-12-19T21:47:06.000Z","date":"2024-12-17","kind":"grant","planned":false,"acquired":true,"shares":27770,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Represents an option of which 1/4 of the shares underlying the option becomes vested and exercisable on February 13, 2025 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter beginning on March 13, 2025, such that the option shall fully vest on February 13, 2028."}],"balance_after":27770,"derivative":{"exercise_price":136.69,"expiration_date":"2034-12-17","underlying":"Common Stock","underlying_shares":27770},"source":{"system":"sec-edgar","filing":"0000914475-24-000226","document":"wk-form4_1734644819.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000226/wk-form4_1734644819.xml","form_type":"4"}},{"id":1325813,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Unit","published_at":"2024-12-19T21:47:06.000Z","date":"2024-12-17","kind":"grant","planned":false,"acquired":true,"shares":5487,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Restricted Stock Units will vest 1/4 of the units on February 13,  2025, and then annually 1/4 of the shares will vest on February 13, 2026, February 13, 2027, and February 13, 2028."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Restricted Stock Units will vest 1/4 of the units on February 13,  2025, and then annually 1/4 of the shares will vest on February 13, 2026, February 13, 2027, and February 13, 2028."}],"balance_after":5487,"derivative":{"underlying":"Common Stock","underlying_shares":5487},"source":{"system":"sec-edgar","filing":"0000914475-24-000226","document":"wk-form4_1734644819.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000226/wk-form4_1734644819.xml","form_type":"4"}},{"id":1369879,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Incentive Stock Option","published_at":"2024-11-12T22:58:47.000Z","date":"2024-11-08","kind":"exercise","planned":false,"acquired":false,"shares":1,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Represents option of which 1/48th of the shares underlying the option became vested and exercisable on February 28, 2022 and an additional 1/48th of the shares underlying the option becomes vested and excercisable each month thereafter."}],"balance_after":1265,"derivative":{"exercise_price":79.02,"expiration_date":"2032-01-31","underlying":"Common Stock","underlying_shares":1},"source":{"system":"sec-edgar","filing":"0000914475-24-000220","document":"wk-form4_1731452320.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000220/wk-form4_1731452320.xml","form_type":"4"}},{"id":1369878,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Incentive Stock Option","published_at":"2024-11-12T22:58:47.000Z","date":"2024-11-08","kind":"exercise","planned":false,"acquired":false,"shares":971,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Represents option of which 1/48th of the shares underlying the option became vested and exercisable on March 6, 2020 and an additional 1/48th of the shares underlying the option became vested and excercisable each month thereafter."}],"balance_after":0,"derivative":{"exercise_price":102.9,"expiration_date":"2030-02-06","underlying":"Common Stock","underlying_shares":971},"source":{"system":"sec-edgar","filing":"0000914475-24-000220","document":"wk-form4_1731452320.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000220/wk-form4_1731452320.xml","form_type":"4"}},{"id":1369877,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Incentive Stock Option","published_at":"2024-11-12T22:58:47.000Z","date":"2024-11-08","kind":"exercise","planned":false,"acquired":false,"shares":1233,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Represents option of which 1/48th of the shares underlying the option became vested and exercisable on March 7, 2019 and an additional 1/48th of the shares underlying the option became vested and excercisable each month thereafter."}],"balance_after":0,"derivative":{"exercise_price":81.05,"expiration_date":"2029-02-07","underlying":"Common Stock","underlying_shares":1233},"source":{"system":"sec-edgar","filing":"0000914475-24-000220","document":"wk-form4_1731452320.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000220/wk-form4_1731452320.xml","form_type":"4"}},{"id":1369876,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Incentive Stock Option","published_at":"2024-11-12T22:58:47.000Z","date":"2024-11-08","kind":"exercise","planned":false,"acquired":false,"shares":5140,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Represents option of which 1/4th of the shares underlying the option became vested and exercisable on January 8, 2019 and an additional 1/48th of the shares underlying the option became vested and excercisable each month thereafter."}],"balance_after":0,"derivative":{"exercise_price":77.81,"expiration_date":"2028-01-08","underlying":"Common Stock","underlying_shares":5140},"source":{"system":"sec-edgar","filing":"0000914475-24-000220","document":"wk-form4_1731452320.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000220/wk-form4_1731452320.xml","form_type":"4"}},{"id":1369875,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-11-12T22:58:47.000Z","date":"2024-11-08","kind":"exercise","planned":false,"acquired":true,"shares":1,"price":79.02,"value":79.02,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction involved a cash exercise of a stock option without a subsequent sale of the underlying shares of common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"29,876 of the outstanding shares are held by The Stephen Tayor and Eiry W. Roberts Joint Trust Agreement, of which Dr. Roberts has voting and investment power."}],"balance_after":31061,"source":{"system":"sec-edgar","filing":"0000914475-24-000220","document":"wk-form4_1731452320.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000220/wk-form4_1731452320.xml","form_type":"4"}},{"id":1369874,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-11-12T22:58:47.000Z","date":"2024-11-08","kind":"exercise","planned":false,"acquired":true,"shares":971,"price":102.9,"value":99915.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction involved a cash exercise of a stock option without a subsequent sale of the underlying shares of common stock."}],"balance_after":31060,"source":{"system":"sec-edgar","filing":"0000914475-24-000220","document":"wk-form4_1731452320.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000220/wk-form4_1731452320.xml","form_type":"4"}},{"id":1369873,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-11-12T22:58:47.000Z","date":"2024-11-08","kind":"exercise","planned":false,"acquired":true,"shares":1233,"price":81.05,"value":99934.65,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction involved a cash exercise of a stock option without a subsequent sale of the underlying shares of common stock."}],"balance_after":30089,"source":{"system":"sec-edgar","filing":"0000914475-24-000220","document":"wk-form4_1731452320.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000220/wk-form4_1731452320.xml","form_type":"4"}},{"id":1369872,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-11-12T22:58:47.000Z","date":"2024-11-08","kind":"exercise","planned":false,"acquired":true,"shares":5140,"price":77.81,"value":399943.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction involved a cash exercise of a stock option without a subsequent sale of the underlying shares of common stock."}],"balance_after":28856,"source":{"system":"sec-edgar","filing":"0000914475-24-000220","document":"wk-form4_1731452320.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000220/wk-form4_1731452320.xml","form_type":"4"}},{"id":1487255,"issuer":{"id":51196,"kind":"organization","name":"AMICUS THERAPEUTICS, INC.","symbol":"FOLD"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2024-06-07T23:52:14.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":42467,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One hundred percent of the shares subject to this option will vest and become exercisable on the one year anniversary of the date of grant."}],"balance_after":42467,"derivative":{"exercise_price":10.27,"expiration_date":"2034-06-06","underlying":"Common Stock","underlying_shares":42467},"source":{"system":"sec-edgar","filing":"0000950170-24-071007","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178879/000095017024071007/ownership.xml","form_type":"4"}},{"id":1487254,"issuer":{"id":51196,"kind":"organization","name":"AMICUS THERAPEUTICS, INC.","symbol":"FOLD"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-07T23:52:14.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":11847,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Granted in the form of Restricted Stock Units (\"RSUs\"), these RSUs will vest in full on the one year anniversary of the grant date and shall be payable in common stock. One (1) RSU is the equivalent of one (1) share of Amicus common stock."}],"balance_after":55861,"source":{"system":"sec-edgar","filing":"0000950170-24-071007","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178879/000095017024071007/ownership.xml","form_type":"4"}},{"id":1641738,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Unit","published_at":"2024-02-15T22:51:27.000Z","date":"2024-02-13","kind":"grant","planned":true,"acquired":true,"shares":4483,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2025, February 13, 2026, February 13, 2027, and February 13, 2028."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2025, February 13, 2026, February 13, 2027, and February 13, 2028."}],"balance_after":4483,"derivative":{"underlying":"Common Stock","underlying_shares":4483},"source":{"system":"sec-edgar","filing":"0000914475-24-000076","document":"wk-form4_1708037478.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000076/wk-form4_1708037478.xml","form_type":"4"}},{"id":1641737,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option","published_at":"2024-02-15T22:51:27.000Z","date":"2024-02-13","kind":"grant","planned":true,"acquired":true,"shares":22529,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2024 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter."}],"balance_after":22529,"derivative":{"exercise_price":133.84,"expiration_date":"2034-02-13","underlying":"Common Stock","underlying_shares":22529},"source":{"system":"sec-edgar","filing":"0000914475-24-000076","document":"wk-form4_1708037478.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000076/wk-form4_1708037478.xml","form_type":"4"}},{"id":1641736,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-02-15T22:51:27.000Z","date":"2024-02-13","kind":"sale","planned":true,"acquired":false,"shares":1114,"price":132.9639,"value":148121.7846,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 1,114 shares of common stock issued upon vesting of 2,113 restricted stock units on February 13, 2024 to cover payroll and withholding taxes, with the balance of the shares (999) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $129.96 to $134.87. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"18,336 of the outstanding shares are held by The Stephen Taylor and Eiry W. Roberts Joint Trust Agreement, of which Dr. Roberts has voting and investment power."}],"balance_after":23716,"source":{"system":"sec-edgar","filing":"0000914475-24-000076","document":"wk-form4_1708037478.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000076/wk-form4_1708037478.xml","form_type":"4"}},{"id":1654160,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-02-09T00:28:57.000Z","date":"2024-02-08","kind":"sale","planned":true,"acquired":false,"shares":980,"price":134.2061,"value":131521.978,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Sale of 980 shares of common stock issued upon vesting of 1,860 restricted stock units on February 8, 2024 to cover payroll and withholding taxes, with the balance of the shares (880) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2021. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $132.64 to $136.34. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"18,336 of the outstanding shares are held by The Stephen Taylor and Eiry W. Roberts Joint Trust Agreement, of which Dr. Roberts has voting and investment power."}],"balance_after":22717,"source":{"system":"sec-edgar","filing":"0000914475-24-000049","document":"wk-form4_1707438524.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000049/wk-form4_1707438524.xml","form_type":"4"}},{"id":1654159,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-02-09T00:28:57.000Z","date":"2024-02-06","kind":"sale","planned":true,"acquired":false,"shares":1121,"price":142.2356,"value":159446.1076,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 1,121 shares of common stock issued upon vesting of 2,126 restricted stock units on February 6, 2024 to cover payroll and withholding taxes, with the balance of the shares (1,005) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2021. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $141.40 to $143.03. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":21837,"source":{"system":"sec-edgar","filing":"0000914475-24-000049","document":"wk-form4_1707438524.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000049/wk-form4_1707438524.xml","form_type":"4"}},{"id":1662752,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-02-03T00:29:10.000Z","date":"2024-01-31","kind":"sale","planned":true,"acquired":false,"shares":1457,"price":140.7906,"value":205131.9042,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 1,457 shares of common stock issued upon vesting of 2,768 restricted stock units on January 31, 2024 to cover payroll and withholding taxes, with the balance of the shares (1,311) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 1, 2022. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $139.75 to $142.05. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"18,336 of the outstanding shares are held by The Stephen Tayor and Eiry W. Roberts Joint Trust Agreement, of which Dr. Roberts has voting and investment power."}],"balance_after":20832,"source":{"system":"sec-edgar","filing":"0000914475-24-000031","document":"wk-form4_1706920138.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000031/wk-form4_1706920138.xml","form_type":"4"}},{"id":1699788,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-12-27T21:15:43.000Z","date":"2023-12-22","kind":"sale","planned":true,"acquired":false,"shares":10000,"price":126.7448,"value":1267448.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted on November 11, 2022. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $125.00 to $128.00. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"18,336 of the outstanding shares are held by The Stephen Tayor and Eiry W. Roberts Joint Trust Agreement, of which Dr. Roberts has voting and investment power"}],"balance_after":19521,"source":{"system":"sec-edgar","filing":"0001209191-23-059774","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123059774/doc4.xml","form_type":"4"}},{"id":1711514,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2023-12-14T22:22:06.000Z","date":"2023-12-12","kind":"exercise","planned":true,"acquired":false,"shares":6947,"price":81.05,"value":563054.35,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Option granted February 7, 2019 and vested monthly over four years."}],"balance_after":39440,"derivative":{"exercise_price":81.05,"expiration_date":"2029-02-02","underlying":"Common Stock","underlying_shares":6947},"source":{"system":"sec-edgar","filing":"0001209191-23-058683","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123058683/doc4.xml","form_type":"4"}},{"id":1711513,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2023-12-14T22:22:06.000Z","date":"2023-12-12","kind":"exercise","planned":true,"acquired":false,"shares":6978,"price":81.05,"value":565566.9,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Option granted February 7, 2019 and vested monthly over four years."}],"balance_after":46387,"derivative":{"exercise_price":81.05,"expiration_date":"2029-02-07","underlying":"Common Stock","underlying_shares":6978},"source":{"system":"sec-edgar","filing":"0001209191-23-058683","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123058683/doc4.xml","form_type":"4"}},{"id":1711512,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-12-14T22:22:06.000Z","date":"2023-12-12","kind":"sale","planned":true,"acquired":false,"shares":6947,"price":120.3079,"value":835778.9813,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2022. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $120.00 to $121.00. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"28,366 of the outstanding shares are held by The Stephen Tayor and Eiry W. Roberts Joint Trust Agreement, of which Dr. Roberts has voting and investment power."}],"balance_after":29521,"source":{"system":"sec-edgar","filing":"0001209191-23-058683","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123058683/doc4.xml","form_type":"4"}},{"id":1711511,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-12-14T22:22:06.000Z","date":"2023-12-12","kind":"exercise","planned":true,"acquired":true,"shares":6947,"price":81.05,"value":563054.35,"ownership":{"direct":true},"balance_after":36468,"source":{"system":"sec-edgar","filing":"0001209191-23-058683","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123058683/doc4.xml","form_type":"4"}},{"id":1711510,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-12-14T22:22:06.000Z","date":"2023-12-12","kind":"sale","planned":true,"acquired":false,"shares":6978,"price":120.3011,"value":839461.0758,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2022. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $120.00 to $121.00. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":29521,"source":{"system":"sec-edgar","filing":"0001209191-23-058683","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123058683/doc4.xml","form_type":"4"}},{"id":1711509,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-12-14T22:22:06.000Z","date":"2023-12-12","kind":"exercise","planned":true,"acquired":true,"shares":6978,"price":81.05,"value":565566.9,"ownership":{"direct":true},"balance_after":36499,"source":{"system":"sec-edgar","filing":"0001209191-23-058683","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123058683/doc4.xml","form_type":"4"}},{"id":1716958,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2023-12-11T23:18:39.000Z","date":"2023-12-08","kind":"exercise","planned":true,"acquired":false,"shares":100,"price":81.05,"value":8105.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"Option granted February 7, 2019 and vested monthly over four years."}],"balance_after":53365,"derivative":{"exercise_price":81.05,"expiration_date":"2029-02-02","underlying":"Common Stock","underlying_shares":100},"source":{"system":"sec-edgar","filing":"0001209191-23-058116","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123058116/doc4.xml","form_type":"4"}},{"id":1716957,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2023-12-11T23:18:39.000Z","date":"2023-12-08","kind":"exercise","planned":true,"acquired":false,"shares":200,"price":81.05,"value":16210.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"Option granted February 7, 2019 and vested monthly over four years."}],"balance_after":53465,"derivative":{"exercise_price":81.05,"expiration_date":"2029-02-07","underlying":"Common Stock","underlying_shares":200},"source":{"system":"sec-edgar","filing":"0001209191-23-058116","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123058116/doc4.xml","form_type":"4"}},{"id":1716956,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2023-12-11T23:18:39.000Z","date":"2023-12-07","kind":"exercise","planned":true,"acquired":false,"shares":11775,"price":81.05,"value":954363.75,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"Option granted February 7, 2019 and vested monthly over four years."}],"balance_after":53665,"derivative":{"exercise_price":81.05,"expiration_date":"2029-02-07","underlying":"Common Stock","underlying_shares":11775},"source":{"system":"sec-edgar","filing":"0001209191-23-058116","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123058116/doc4.xml","form_type":"4"}},{"id":1716955,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2023-12-11T23:18:39.000Z","date":"2023-12-07","kind":"exercise","planned":true,"acquired":false,"shares":14140,"price":79.02,"value":1117342.8,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Option granted January 31, 2022 and vested monthly over four years."}],"balance_after":60005,"derivative":{"exercise_price":79.02,"expiration_date":"2032-01-31","underlying":"Common Stock","underlying_shares":14140},"source":{"system":"sec-edgar","filing":"0001209191-23-058116","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123058116/doc4.xml","form_type":"4"}},{"id":1716954,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2023-12-11T23:18:39.000Z","date":"2023-12-07","kind":"exercise","planned":true,"acquired":false,"shares":12742,"price":77.81,"value":991455.02,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Option granted January 8, 2018 and vests at 25% upon first anniversary (January 8, 2019) and remaining 75% vesting in 36 equal monthly installments beginning February 8, 2019."}],"balance_after":0,"derivative":{"exercise_price":77.81,"expiration_date":"2028-01-08","underlying":"Common Stock","underlying_shares":12742},"source":{"system":"sec-edgar","filing":"0001209191-23-058116","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123058116/doc4.xml","form_type":"4"}},{"id":1716953,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2023-12-11T23:18:39.000Z","date":"2023-12-07","kind":"exercise","planned":true,"acquired":false,"shares":38722,"price":77.81,"value":3012958.82,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Option granted January 8, 2018 and vests at 25% upon first anniversary (January 8, 2019) and remaining 75% vesting in 36 equal monthly installments beginning February 8, 2019."}],"balance_after":12742,"derivative":{"exercise_price":77.81,"expiration_date":"2028-01-08","underlying":"Common Stock","underlying_shares":38722},"source":{"system":"sec-edgar","filing":"0001209191-23-058116","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123058116/doc4.xml","form_type":"4"}},{"id":1716952,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-12-11T23:18:39.000Z","date":"2023-12-08","kind":"sale","planned":true,"acquired":false,"shares":100,"price":120,"value":12000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2022. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"28,366 of the outstanding shares are held by The Stephen Tayor and Eiry W. Roberts Joint Trust Agreement, of which Dr. Roberts has voting and investment power."}],"balance_after":29521,"source":{"system":"sec-edgar","filing":"0001209191-23-058116","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123058116/doc4.xml","form_type":"4"}},{"id":1716951,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-12-11T23:18:39.000Z","date":"2023-12-08","kind":"exercise","planned":true,"acquired":true,"shares":100,"price":81.05,"value":8105.0,"ownership":{"direct":true},"balance_after":29621,"source":{"system":"sec-edgar","filing":"0001209191-23-058116","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123058116/doc4.xml","form_type":"4"}},{"id":1716950,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-12-11T23:18:39.000Z","date":"2023-12-08","kind":"sale","planned":true,"acquired":false,"shares":200,"price":120.155,"value":24031.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2022. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $120.00 to $120.31. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":29521,"source":{"system":"sec-edgar","filing":"0001209191-23-058116","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123058116/doc4.xml","form_type":"4"}},{"id":1716949,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-12-11T23:18:39.000Z","date":"2023-12-08","kind":"exercise","planned":true,"acquired":true,"shares":200,"price":81.05,"value":16210.0,"ownership":{"direct":true},"balance_after":29721,"source":{"system":"sec-edgar","filing":"0001209191-23-058116","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123058116/doc4.xml","form_type":"4"}},{"id":1716948,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-12-11T23:18:39.000Z","date":"2023-12-07","kind":"sale","planned":true,"acquired":false,"shares":11775,"price":120.3715,"value":1417374.4125,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2022. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $120.00 to $121.25. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":29521,"source":{"system":"sec-edgar","filing":"0001209191-23-058116","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123058116/doc4.xml","form_type":"4"}},{"id":1716947,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-12-11T23:18:39.000Z","date":"2023-12-07","kind":"exercise","planned":true,"acquired":true,"shares":11775,"price":81.05,"value":954363.75,"ownership":{"direct":true},"balance_after":41296,"source":{"system":"sec-edgar","filing":"0001209191-23-058116","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123058116/doc4.xml","form_type":"4"}},{"id":1716946,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-12-11T23:18:39.000Z","date":"2023-12-07","kind":"sale","planned":true,"acquired":false,"shares":14140,"price":120.3715,"value":1702053.01,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2022. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $120.00 to $121.25. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":29521,"source":{"system":"sec-edgar","filing":"0001209191-23-058116","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123058116/doc4.xml","form_type":"4"}},{"id":1716945,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-12-11T23:18:39.000Z","date":"2023-12-07","kind":"exercise","planned":true,"acquired":true,"shares":14140,"price":79.02,"value":1117342.8,"ownership":{"direct":true},"balance_after":43661,"source":{"system":"sec-edgar","filing":"0001209191-23-058116","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123058116/doc4.xml","form_type":"4"}},{"id":1716944,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-12-11T23:18:39.000Z","date":"2023-12-07","kind":"sale","planned":true,"acquired":false,"shares":12742,"price":120.3715,"value":1533773.653,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2022. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $120.00 to $121.25. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":29521,"source":{"system":"sec-edgar","filing":"0001209191-23-058116","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123058116/doc4.xml","form_type":"4"}},{"id":1716943,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-12-11T23:18:39.000Z","date":"2023-12-07","kind":"exercise","planned":true,"acquired":true,"shares":12742,"price":77.81,"value":991455.02,"ownership":{"direct":true},"balance_after":42263,"source":{"system":"sec-edgar","filing":"0001209191-23-058116","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123058116/doc4.xml","form_type":"4"}},{"id":1716942,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-12-11T23:18:39.000Z","date":"2023-12-07","kind":"sale","planned":true,"acquired":false,"shares":38722,"price":120.3739,"value":4661118.1558,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2022. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $120.00 to $121.18. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":29521,"source":{"system":"sec-edgar","filing":"0001209191-23-058116","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123058116/doc4.xml","form_type":"4"}},{"id":1716941,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-12-11T23:18:39.000Z","date":"2023-12-07","kind":"exercise","planned":true,"acquired":true,"shares":38722,"price":77.81,"value":3012958.82,"ownership":{"direct":true},"balance_after":68243,"source":{"system":"sec-edgar","filing":"0001209191-23-058116","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123058116/doc4.xml","form_type":"4"}},{"id":1718345,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2023-12-09T00:09:44.000Z","date":"2023-12-06","kind":"exercise","planned":true,"acquired":false,"shares":8396,"price":77.81,"value":653292.76,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Option granted January 8, 2018 and vests at 25% upon first anniversary (January 8, 2019) and remaining 75% vesting in 36 equal monthly installments beginning February 8, 2019."}],"balance_after":51464,"derivative":{"exercise_price":77.81,"expiration_date":"2028-01-08","underlying":"Common Stock","underlying_shares":8396},"source":{"system":"sec-edgar","filing":"0001209191-23-057986","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123057986/doc4.xml","form_type":"4"}},{"id":1718344,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-12-09T00:09:44.000Z","date":"2023-12-06","kind":"sale","planned":true,"acquired":false,"shares":8396,"price":120.031,"value":1007780.276,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2022. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $120.00 to $120.20. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"28,336 of the outstanding shares are held by The Stephen Tayor and Eiry W. Roberts Joint Trust Agreement, of which Dr. Roberts has voting and investment power."}],"balance_after":29521,"source":{"system":"sec-edgar","filing":"0001209191-23-057986","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123057986/doc4.xml","form_type":"4"}},{"id":1718343,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-12-09T00:09:44.000Z","date":"2023-12-06","kind":"exercise","planned":true,"acquired":true,"shares":8396,"price":77.81,"value":653292.76,"ownership":{"direct":true},"balance_after":37917,"source":{"system":"sec-edgar","filing":"0001209191-23-057986","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123057986/doc4.xml","form_type":"4"}},{"id":1799017,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-08-24T00:20:07.000Z","date":"2023-08-21","kind":"sale","planned":true,"acquired":false,"shares":3198,"price":107.3758,"value":343387.8084,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 3,198 shares of common stock issued upon vesting of 6,075 performance restricted stock units on August 21, 2023 to cover payroll and withholding taxes, with the balance of the shares (2,877) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The Reporting Person was previously granted performance restricted stock units that vest upon the achievement of certain milestones that occurred on August 21, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $107.05 to $108.42. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"25,459 of the outstanding shares are held by The Stephen Tayor and Eiry W. Roberts Joint Trust Agreement, of which Dr. Roberts has voting and investment power."}],"balance_after":29521,"source":{"system":"sec-edgar","filing":"0001209191-23-047140","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123047140/doc4.xml","form_type":"4"}},{"id":1859199,"issuer":{"id":51196,"kind":"organization","name":"AMICUS THERAPEUTICS, INC.","symbol":"FOLD"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2023-06-12T21:38:02.000Z","date":"2023-06-08","kind":"grant","planned":false,"acquired":true,"shares":30474,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One hundred percent of the shares subject to this option will vest and become exercisable on the one year anniversary of the date of grant."}],"balance_after":30474,"derivative":{"exercise_price":12.62,"expiration_date":"2033-06-08","underlying":"Common Stock","underlying_shares":30474},"source":{"system":"sec-edgar","filing":"0001209191-23-036422","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178879/000120919123036422/doc4.xml","form_type":"4"}},{"id":1859198,"issuer":{"id":51196,"kind":"organization","name":"AMICUS THERAPEUTICS, INC.","symbol":"FOLD"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-12T21:38:02.000Z","date":"2023-06-08","kind":"grant","planned":false,"acquired":true,"shares":8584,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Granted in the form of Restricted Stock Units (\"RSUs\"), these RSUs will vest in full on the one year anniversary of the grant date and shall be payable in common stock. One (1) RSU is the equivalent of one (1) share of Amicus common stock."}],"balance_after":44014,"source":{"system":"sec-edgar","filing":"0001209191-23-036422","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178879/000120919123036422/doc4.xml","form_type":"4"}},{"id":1913621,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-04-27T01:22:18.000Z","date":"2023-04-24","kind":"sale","planned":true,"acquired":false,"shares":14400,"price":103.4763,"value":1490058.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted on February 23, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $102.84 to $104.15. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":26644,"source":{"system":"sec-edgar","filing":"0001209191-23-025763","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123025763/doc4.xml","form_type":"4"}},{"id":2014209,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Unit","published_at":"2023-02-16T00:15:54.000Z","date":"2023-02-13","kind":"grant","acquired":true,"shares":8453,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2024, February 13, 2025, February 13, 2026, and February 13, 2027."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2024, February 13, 2025, February 13, 2026, and February 13, 2027."}],"balance_after":8453,"derivative":{"underlying":"Common Stock","underlying_shares":8453},"source":{"system":"sec-edgar","filing":"0001209191-23-009889","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123009889/doc4.xml","form_type":"4"}},{"id":2014208,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option","published_at":"2023-02-16T00:15:54.000Z","date":"2023-02-13","kind":"grant","acquired":true,"shares":52532,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2023 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter."}],"balance_after":52532,"derivative":{"exercise_price":103.52,"expiration_date":"2033-02-13","underlying":"Common Stock","underlying_shares":52532},"source":{"system":"sec-edgar","filing":"0001209191-23-009889","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123009889/doc4.xml","form_type":"4"}},{"id":2027011,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-02-09T00:40:58.000Z","date":"2023-02-08","kind":"sale","acquired":false,"shares":980,"price":104.1551,"value":102071.998,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F8","text":"Sale of 980 shares of common stock issued upon vesting of 1,860 restricted stock units on February 8, 2023 to cover payroll and withholding taxes, with the balance of the shares (880) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $101.79 to $106.05. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":41015,"source":{"system":"sec-edgar","filing":"0001209191-23-007916","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123007916/doc4.xml","form_type":"4"}},{"id":2027010,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-02-09T00:40:58.000Z","date":"2023-02-07","kind":"sale","acquired":false,"shares":12801,"price":102.4075,"value":1310918.4075,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Sale of 12,801 shares of common stock issued upon vesting of 24,298 performance restricted stock units on February 7, 2023 to cover payroll and withholding taxes, with the balance of the shares (11,497) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"kind","element":"transactionCoding","label":"F6","text":"The Reporting Person was previously granted performance restricted stock units that vest upon the achievement of certain milestones that occurred on February 7, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $100.00 to $103.89 The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":40135,"source":{"system":"sec-edgar","filing":"0001209191-23-007916","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123007916/doc4.xml","form_type":"4"}},{"id":2027009,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-02-09T00:40:58.000Z","date":"2023-02-07","kind":"sale","acquired":false,"shares":1623,"price":102.35,"value":166114.05,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Sale of 1,623 shares of common stock issued upon vesting of 3,085 restricted stock units on February 7, 2023 to cover payroll and withholding taxes, with the balance of the shares (1,462) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $100.56 to $103.87 The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":28638,"source":{"system":"sec-edgar","filing":"0001209191-23-007916","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123007916/doc4.xml","form_type":"4"}},{"id":2027008,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-02-09T00:40:58.000Z","date":"2023-02-06","kind":"sale","acquired":false,"shares":1121,"price":105.8004,"value":118602.2484,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 1,121 shares of common stock issued upon vesting of 2,126 restricted stock units on February 6, 2023 to cover payroll and withholding taxes, with the balance of the shares (1,005) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $104.99 to $108.36. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":27176,"source":{"system":"sec-edgar","filing":"0001209191-23-007916","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123007916/doc4.xml","form_type":"4"}},{"id":2037158,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-02-02T22:28:27.000Z","date":"2023-01-31","kind":"sale","acquired":false,"shares":1457,"price":109.9887,"value":160253.5359,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 1,457 shares of common stock issued upon vesting of 2,768 restricted stock units on January 31, 2023 to cover payroll and withholding taxes, with the balance of the shares (1,311) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $109.07 to $110.87. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":26171,"source":{"system":"sec-edgar","filing":"0001209191-23-006282","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123006282/doc4.xml","form_type":"4"}},{"id":2236447,"issuer":{"id":51196,"kind":"organization","name":"AMICUS THERAPEUTICS, INC.","symbol":"FOLD"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2022-06-10T20:11:38.000Z","date":"2022-06-09","kind":"grant","acquired":true,"shares":45423,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One hundred percent of the shares subject to this option will vest and become exercisable on the one year anniversary of the date of grant."}],"balance_after":45423,"derivative":{"exercise_price":8.55,"expiration_date":"2032-06-09","underlying":"Common Stock","underlying_shares":45423},"source":{"system":"sec-edgar","filing":"0001209191-22-035847","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178879/000120919122035847/doc4.xml","form_type":"4"}},{"id":2236446,"issuer":{"id":51196,"kind":"organization","name":"AMICUS THERAPEUTICS, INC.","symbol":"FOLD"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-10T20:11:38.000Z","date":"2022-06-09","kind":"grant","acquired":true,"shares":12671,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Granted in the form of Restricted Stock Units (\"RSUs\"), these RSUs will vest in full on the one year anniversary of the grant date and shall be payable in common stock. One (1) RSU is the equivalent of one (1) share of Amicus common stock."}],"balance_after":35430,"source":{"system":"sec-edgar","filing":"0001209191-22-035847","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178879/000120919122035847/doc4.xml","form_type":"4"}},{"id":2406986,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-02-10T00:06:02.000Z","date":"2022-02-08","kind":"sale","acquired":false,"shares":980,"price":79.521,"value":77930.58,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Sale of 980 shares of common stock issued upon vesting of 1,859 restricted stock units on February 8, 2022 to cover payroll and withholding taxes, with the balance of the shares (879) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $79.10 to $79.96 The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":24625,"source":{"system":"sec-edgar","filing":"0001209191-22-008216","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919122008216/doc4.xml","form_type":"4"}},{"id":2406985,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-02-10T00:06:02.000Z","date":"2022-02-07","kind":"sale","acquired":false,"shares":1121,"price":80.7975,"value":90573.9975,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Sale of 1,121 shares of common stock issued upon vesting of 2,126 restricted stock units on February 7, 2022 to cover payroll and withholding taxes, with the balance of the shares (1,005) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $79.99 to $81.36 The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":23746,"source":{"system":"sec-edgar","filing":"0001209191-22-008216","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919122008216/doc4.xml","form_type":"4"}},{"id":2406984,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-02-10T00:06:02.000Z","date":"2022-02-07","kind":"sale","acquired":false,"shares":1623,"price":80.7676,"value":131085.8148,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 1,623 shares of common stock issued upon vesting of 3,085 restricted stock units on February 7, 2022 to cover payroll and withholding taxes, with the balance of the shares (1,462) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $79.76 to $81.35. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":22741,"source":{"system":"sec-edgar","filing":"0001209191-22-008216","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919122008216/doc4.xml","form_type":"4"}},{"id":2417557,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Unit","published_at":"2022-02-03T00:52:47.000Z","date":"2022-01-31","kind":"grant","acquired":true,"shares":11074,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of January 31, 2023, January 31, 2024, January 31, 2025, and January 31, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of January 31, 2023, January 31, 2024, January 31, 2025, and January 31, 2026."}],"balance_after":11074,"derivative":{"underlying":"Common Stock","underlying_shares":11074},"source":{"system":"sec-edgar","filing":"0001209191-22-006582","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919122006582/doc4.xml","form_type":"4"}},{"id":2417556,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option","published_at":"2022-02-03T00:52:47.000Z","date":"2022-01-31","kind":"grant","acquired":true,"shares":75411,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on February 28, 2022 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter."}],"balance_after":75411,"derivative":{"exercise_price":79.02,"expiration_date":"2032-01-31","underlying":"Common Stock","underlying_shares":75411},"source":{"system":"sec-edgar","filing":"0001209191-22-006582","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919122006582/doc4.xml","form_type":"4"}},{"id":2437148,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-01-12T22:53:57.000Z","date":"2022-01-10","kind":"sale","acquired":false,"shares":2632,"price":74.5014,"value":196087.6848,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 2,632 shares of common stock issued upon vesting of 5,000 restricted stock units on January 10, 2022 to cover payroll and withholding taxes, with the balance of the shares (2,368) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"shares","element":"transactionShares","label":"F1","text":"Sale of 2,632 shares of common stock issued upon vesting of 5,000 restricted stock units on January 10, 2022 to cover payroll and withholding taxes, with the balance of the shares (2,368) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $72.14 to $76.40. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes an aggregate of 218 shares purchased on February 26, 2021 and August 31, 2021 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan."}],"balance_after":21279,"source":{"system":"sec-edgar","filing":"0001209191-22-003104","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919122003104/doc4.xml","form_type":"4"}},{"id":2670488,"issuer":{"id":51196,"kind":"organization","name":"AMICUS THERAPEUTICS, INC.","symbol":"FOLD"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2021-06-14T23:04:37.000Z","date":"2021-06-10","kind":"grant","acquired":true,"shares":40625,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These stock options vest and become exercisable over a period of four years, with 25% vesting on the first anniversary of the date of grant and the remainder vesting ratably each month thereafter."}],"balance_after":40625,"derivative":{"exercise_price":10.71,"expiration_date":"2031-06-10","underlying":"Common Stock","underlying_shares":40625},"source":{"system":"sec-edgar","filing":"0001209191-21-040374","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178879/000120919121040374/doc4.xml","form_type":"4"}},{"id":2670487,"issuer":{"id":51196,"kind":"organization","name":"AMICUS THERAPEUTICS, INC.","symbol":"FOLD"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-14T23:04:37.000Z","date":"2021-06-10","kind":"grant","acquired":true,"shares":22759,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted stock units (RSUs) vest over a period of four years, with 25% vesting on the first anniversary of the grant date and 25% on each anniversary thereafter."}],"balance_after":22759,"source":{"system":"sec-edgar","filing":"0001209191-21-040374","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178879/000120919121040374/doc4.xml","form_type":"4"}},{"id":2769851,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option","published_at":"2021-03-29T10:24:55.000Z","date":"2021-02-08","kind":"grant","acquired":true,"shares":49049,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 8, 2021 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter."}],"balance_after":49049,"derivative":{"exercise_price":117.63,"expiration_date":"2031-02-08","underlying":"Common Stock","underlying_shares":49049},"source":{"system":"sec-edgar","filing":"0001209191-21-023387","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919121023387/doc4a.xml","form_type":"4/A","original_submission_date":"2021-02-09"}},{"id":2872955,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Unit","published_at":"2021-02-10T02:21:38.000Z","date":"2021-02-08","kind":"grant","acquired":true,"shares":7439,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 8, 2022, February 8, 2023, February 8, 2024, and February 8, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 8, 2022, February 8, 2023, February 8, 2024, and February 8, 2025."}],"balance_after":7439,"derivative":{"underlying":"Common Stock","underlying_shares":7439},"source":{"system":"sec-edgar","filing":"0001209191-21-009123","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919121009123/doc4.xml","form_type":"4"}},{"id":2872954,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option","published_at":"2021-02-10T02:21:38.000Z","date":"2021-02-08","kind":"grant","acquired":true,"shares":44632,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 8, 2021 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter."}],"balance_after":44632,"derivative":{"exercise_price":117.63,"expiration_date":"2031-02-08","underlying":"Common Stock","underlying_shares":44632},"source":{"system":"sec-edgar","filing":"0001209191-21-009123","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919121009123/doc4.xml","form_type":"4"}},{"id":2872953,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-02-10T02:21:38.000Z","date":"2021-02-08","kind":"sale","acquired":false,"shares":1623,"price":116.8252,"value":189607.2996,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Sale of 1,623 shares of common stock issued upon vesting of 3,085 restricted stock units on February 8, 2021 to cover payroll and withholding taxes, with the balance of the shares (1,462) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.99 to $117.88. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":18693,"source":{"system":"sec-edgar","filing":"0001209191-21-009123","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919121009123/doc4.xml","form_type":"4"}},{"id":2872952,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-02-10T02:21:38.000Z","date":"2021-02-08","kind":"sale","acquired":false,"shares":740,"price":116.6711,"value":86336.614,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 740 shares of common stock issued upon vesting of 2,126 restricted stock units on February 8, 2021 to cover payroll and withholding taxes, with the balance of the shares (1,386) maintained by the Reporting Person. The disposition reported in this Form 4 was effected by a broker pursuant to instructions consistent with Rule 10b5-1 at least 60 days prior to the transaction date in Box 3 above."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.98 to $117.20. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":17231,"source":{"system":"sec-edgar","filing":"0001209191-21-009123","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919121009123/doc4.xml","form_type":"4"}},{"id":2909937,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-01-12T21:17:59.000Z","date":"2021-01-08","kind":"sale","acquired":false,"shares":2632,"price":111.0552,"value":292297.2864,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 2,632 shares of common stock issued upon vesting of 5,000 restricted stock units on January 8, 2021 to cover payroll and withholding taxes, with the balance of the shares (2,368) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $104.10 to $112.70. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":15845,"source":{"system":"sec-edgar","filing":"0001209191-21-003239","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919121003239/doc4.xml","form_type":"4"}},{"id":2980251,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":44455,"kind":"person","name":"ROBERTS EIRY","position":1,"cik":"0001727606","reported_name":"ROBERTS EIRY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-11-16T23:23:59.000Z","date":"2020-11-12","kind":"sale","acquired":false,"shares":2257,"price":90.7443,"value":204809.8851,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 2,257 shares of common stock issued upon vesting of 4,288 performance restricted stock units to cover withholding taxes, with the balance of the shares (2,031) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $88.93 to $92.27. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":13477,"source":{"system":"sec-edgar","filing":"0001209191-20-058553","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120058553/doc4.xml","form_type":"4"}}],"next_cursor":"2020-11-16T23:23:59.000000Z,2980251"}